[Yu Jin-hee, Edaily Reporter] Amid broader market volatility on Thursday, South Korea’s biopharmaceutical sector lacked a clear directional trend, leaving traditional, profitable pharmaceutical and biotech firms to anchor investor sentiment.

While stocks backed by solid fundamentals maintained steady gains despite heightened volatility, companies exposed to supply-demand imbalances and financial risks experienced extreme price swings, facing harsh market realities.

GC Genome Rises on Progress in U.S. Pancreatic Cancer Test and Solid Earnings

According to KG Zeroin MP Doctor, representative biotech stocks posting double-digit fluctuations among the day’s top gainers and losers included Moalife Plus, GC Genome, and Baropharm.

Their share prices diverged sharply: Moalife Plus surged 30.00% to close at 117 won, GC Genome rose 13.20% to 8,400 won, and Baropharm tumbled 18.42% to 9,610 won.

Market analysts noted that the newly listed Baropharm faced immediate overhang (potential sell-off volume) pressures, while Moalife Plus suffered from supply-demand imbalances after its parent company triggered an event of default (EOD). In contrast, GC Genome served as a stabilizing force for sector sentiment, supported by steady core profits and tangible progress toward U.S. commercialization.

Buying interest in GC Genome was driven by consistent domestic profitability and expectations for the U.S. launch of its early-stage pancreatic cancer screening test. Brokerage firms have highlighted the company’s steep earnings trajectory. Korea Investment & Securities projected in a recent report that GC Genome’s third-quarter consolidated revenue rose 17.8% year-over-year to 10.4 billion won, with operating profit jumping 31.3% to 1 billion won.

With an estimated operating margin of 9.7%, the company is expected to extend its streak of consecutive quarterly operating profits, which began in the second quarter of last year. Samsung Securities also gave a positive assessment of GC Genome’s five-quarter profit streak, citing first-half revenue of 15.7 billion won (up 8% year-on-year) and operating profit of 600 million won (up 119% year-on-year).

Core domestic diagnostic services remain the backbone of this performance. The volume of G-NIPT—a non-invasive prenatal test that analyzes fetal DNA in maternal blood for chromosomal abnormalities—grew steadily from 14,000 tests in 2023 to 18,000 in 2024 and 25,200 last year, approaching 30,000 tests this year.

Meanwhile, ai-CANCERCH, a non-reimbursed multi-cancer early detection test utilizing cell-free DNA, has gained traction across all domestic tertiary general hospitals and roughly 40% of general hospitals. Test volume surged from 900 in 2024 to 5,100 last year and has already surpassed 4,100 in the first half of this year, with the number of corporate clients expected to expand to around 160 by year-end.

Exports to Japan, which began in the first quarter, along with anticipated local Japanese certification in the first quarter of next year, serve as additional growth drivers. However, the key catalyst for a medium- to long-term valuation re-rating is Pancsight, an early pancreatic cancer screening test targeting the U.S. market. Developed by affiliate GC LabTech—in which GC Genome holds a 24.1% stake—Pancsight demonstrated encouraging U.S. clinical results across 2,800 samples, achieving 93.7% sensitivity and 95.4% specificity. Notably, sensitivity for early-stage (Stages I and II) pancreatic cancer, which is critical to patient prognosis, reached 87.5%.

Based on this clinical data, GC Genome plans to submit a pre-submission package to the U.S. Food and Drug Administration (FDA) this month, apply for Breakthrough Device Designation (BDD) by the first quarter of next year, complete clearance procedures within the year, and launch the product commercially the following year. U.S. distribution will be handled by Guardant Health, a global leader in liquid biopsy with an established commercial network built around its colorectal cancer test, Guardant Shield.

“By leveraging the strong hospital network of its traditional pharmaceutical group and stable cash generation, GC Genome is entering high-value overseas diagnostic markets,” said a brokerage official. “If U.S. distribution partnerships proceed smoothly and prospective clinical data accumulates to support insurance reimbursement, achieving its 2028 target for U.S. Laboratory-Developed Test (LDT) commercialization and insurance code listing is well within reach.”

Baropharm Tumbles as Venture Capitalists Exit Immediately After IPO

While GC Genome rode a wave of core competitiveness, Baropharm, an operator of a pharmacy-integrated platform, suffered a dismal post-IPO debut due to massive profit-taking sell-offs. Following a plunge of over 28% on its November 11 listing debut, the stock extended its steep decline for a second consecutive day, falling well below its IPO price range of 16,400 to 20,200 won.

The immediate trigger for the sell-off was exit volume from early financial investors (FIs), specifically venture capital (VC) funds. The Korea Exchange (KRX) designated Baropharm as an “investment caution stock due to high single-account trading volume” for November 12 after a single account net sold 433,836 shares—3.63% of total listed shares—on the debut day.

Under KRX classification systems, unincorporated venture funds are categorized as “retail” accounts, and market participants point to the KB Global Platform Fund as the seller. Essentially, the entire tradable, non-lockup portion (433,836 shares) of the fund’s 867,673-share stake was dumped onto the market on the listing day.

Despite severe supply-and-demand headwinds weighing on the stock, analysts largely view Baropharm’s business fundamentals as sound. Founded in 2019 by pharmacist Kim Seul-gi, Baropharm is South Korea’s largest pharmacy order-integration platform, with 24,787 pharmacies—over 90% of the nation’s total—as members.

Capitalizing on an overwhelming cumulative Total Gross Merchandise Value (TGMV) of 7.2 trillion won, the company expanded into direct-purchase distribution (BMS) and private brand (PB) businesses, achieving a turnaround in earnings. Consolidated Q3 revenue jumped 77.9% year-on-year to 49.6 billion won, resulting in an operating profit of 2.3 billion won.

Building on first-half revenue of 69 billion won and an operating profit of 2.2 billion won, Baropharm is accelerating its healthcare Artificial Intelligence Transformation (AX) ecosystem using IPO proceeds. Early next year, the company will officially launch “BaroAI,” an AI agent designed specifically for pharmacists and trained on 7 trillion won worth of real transaction data, alongside a drug supply-and-demand forecasting and automated ordering engine, while expanding into the physician platform “BaroMD” and a telemedicine prescription linkage solution (BPCS).

The company also plans to invest 14 billion won to expand manufacturing facilities at its subsidiary, CHD Pharm, to boost in-house production and lower its cost-of-goods-sold ratio below 50%, shifting away from low-margin direct distribution toward a high-margin structure.

However, resolving lingering overhang risks remains a prerequisite for a near-term share price recovery, as approximately 780,000 tradable shares held by major shareholders—including Company K New Deal Fund (213,776 shares) and KB Digital Platform Fund (257,834 shares)—remain poised for potential release.

“Although Baropharm has clear strengths in its dominant market position and profit turnaround, it is undergoing an excessive correction due to post-IPO supply-demand imbalances,” said a financial investment industry official. “A true valuation re-rating will occur only after the three-month put-back option window for retail subscribers passes and the existing venture capital (VC) overhang is absorbed.”

The Paradox of Moalife Plus’s Limit-Up Surge Amid Its Parent Company’s Default Crisis

Moalife Plus, which hit the daily upper price limit to top the market’s gainers list, faces a precarious crisis beneath its superficial rally. Caught between positive biotech licensing news and severe liquidity distress—along with creditors’ enforcement of collateral at parent company Moadata—market observers view the surge with caution as a classic “dead cat bounce” or speculative volatility driven by distorted supply and demand.

On November 10, Moalife Plus plummeted following a massive net sell-off of 679,649 shares—3.12% of its 21,779,615 listed shares—from a single corporate account, prompting the KRX to designate it an “investment caution” stock on November 11.

Behind the sell-off lies the cascading financial deterioration at parent company Moadata. The AI-based anomaly detection firm posted an operating loss of 5.93 billion won last year due to slumps in its core business, followed by a 3.7 billion won deficit in the first half of this year, severely eroding its cash generation.

As refinancing through mezzanine debt—such as convertible bonds (CBs) and bonds with warrants (BWs)—hit a wall, the crisis spiraled out of control. In August, Moadata received an end-of-day (EOD) notice from Sangsangin Savings Bank regarding 4.84 billion won in overdue loans, and its debt-to-equity ratio surged to 570% by the end of the first half of the year following derivative valuation losses.

Crucially, Moadata had pledged 6.1 million shares of its subsidiary Moalife Plus as loan collateral, while Moalife Plus’s holdings of Moadata’s bonds with warrants and common shares were also tied up as collateral, pushing the entire group’s governance and liquidity toward collapse.

On November 4, creditor Sangsangin Savings Bank disclosed that it had acquired the right to dispose of approximately 1.73 million Moadata shares and mezzanine securities as collateral due to the EOD. When Moadata resumed trading on November 11, a wave of forced margin call selling sent the stock plummeting to its daily lower limit. Exposed to contagion risks and pressure from creditors to liquidate collateral, Moalife Plus also tumbled into penny-stock territory, trading in the 100-won range.

Nevertheless, Moalife Plus’s underlying drug pipeline continues to attract market interest. Muscle-wasting treatment candidates EL-22 (formerly BLS-M22) and EL-32 (formerly BLS-M32), licensed to the U.S. biotech firm NorthStrive Biosciences, are gaining attention as potential solutions to muscle loss side effects associated with Glucagon-Like Peptide-1 (GLP-1) obesity drugs.

NorthStrive initiated comparability studies between U.S.-manufactured and existing drug substances in August in preparation for a Phase 2 Investigational New Drug (IND) filing. In September, the company also filed a U.S. patent application for preventing microgravity-induced muscle loss during long-duration spaceflight, thereby broadening its therapeutic scope. Moalife Plus stands to receive a $3 million (approx. 4 billion won) milestone payment upon the initiation of U.S. Phase 2 clinical trials.

Industry experts advise separating Moalife Plus’s technological potential from its group governance risks.

“While it is encouraging that Moalife Plus’s obesity and space-related muscle loss pipelines are progressing through its global partner, current share price swings stem from a distorted clash between forced collateral liquidations triggered by its parent company’s EOD and bargain-hunting, rather than the drug’s intrinsic value,” said a biotech industry official. “Investors must exercise extreme caution regarding violent price volatility until Moadata’s delays in reselling treasury bonds and its creditors’ collateral disposal issues are fully resolved.”